Sort   by:  
 Page size 
UnknownCOVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
Not available
S-EPMC8813209 | biostudies-literature
UnknownInfliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Not available
S-EPMC9578965 | biostudies-literature
UnknownNeutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
Not available
S-EPMC10570718 | biostudies-literature
UnknownCOVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Not available
S-EPMC9458592 | biostudies-literature
Sort   by:  
 Page size